Core Laboratories NV (NYSE:CLB) had its price target trimmed by Citigroup Inc. from $116.00 to $110.00 in a research report sent to investors on Wednesday. The firm currently has a neutral rating on the stock.
Several other research firms also recently weighed in on CLB. Credit Suisse Group AG started coverage on shares of Core Laboratories NV in a report on Thursday, September 1st. They issued a neutral rating and a $115.00 target price for the company. Zacks Investment Research downgraded shares of Core Laboratories NV from a strong-buy rating to a hold rating in a report on Tuesday, July 26th. JPMorgan Chase & Co. started coverage on shares of Core Laboratories NV in a report on Friday, June 10th. They issued an overweight rating and a $120.00 target price for the company. Finally, KLR Group reiterated a buy rating and issued a $180.00 target price (up previously from $166.00) on shares of Core Laboratories NV in a report on Monday, June 13th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $120.47.
Shares of Core Laboratories NV (NYSE:CLB) opened at 112.33 on Wednesday. The firm’s 50-day moving average price is $111.92 and its 200-day moving average price is $117.51. The stock has a market cap of $4.95 billion, a price-to-earnings ratio of 59.59 and a beta of 1.45. Core Laboratories NV has a 12-month low of $84.50 and a 12-month high of $135.49.
Core Laboratories NV (NYSE:CLB) last posted its earnings results on Wednesday, July 20th. The company reported $0.35 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.35. Core Laboratories NV had a net margin of 11.81% and a return on equity of 344.55%. The firm earned $148.10 million during the quarter, compared to the consensus estimate of $146.37 million. During the same quarter last year, the firm earned $0.81 EPS. The firm’s revenue for the quarter was down 27.4% on a year-over-year basis. On average, analysts forecast that Core Laboratories NV will post $1.55 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in the stock. Emerald Acquisition Ltd. acquired a new stake in shares of Core Laboratories NV during the second quarter worth approximately $110,515,000. Royal Bank of Canada boosted its stake in shares of Core Laboratories NV by 416.8% in the second quarter. Royal Bank of Canada now owns 475,077 shares of the company’s stock worth $58,857,000 after buying an additional 383,153 shares during the last quarter. Norges Bank acquired a new stake in shares of Core Laboratories NV during the fourth quarter worth approximately $38,759,000. Bessemer Group Inc. boosted its stake in shares of Core Laboratories NV by 40.0% in the first quarter. Bessemer Group Inc. now owns 1,102,126 shares of the company’s stock worth $123,890,000 after buying an additional 315,123 shares during the last quarter. Finally, Fiera Capital Corp acquired a new stake in shares of Core Laboratories NV during the second quarter worth approximately $26,853,000.
About Core Laboratories NV
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.